Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
about
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceThe potential for emerging therapeutic options for Clostridium difficile infectionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionTrends in Clostridium difficile Disease: Epidemiology and InterventionRifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficileProgress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseasesThe ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challengeEmergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in PolandClostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?Clostridium difficile infection in the intensive care unit.Biologic properties and clinical uses of rifaximin.Treatment of refractory and recurrent Clostridium difficile infection.Recent derivatives from smaller classes of fermentation-derived antibacterials.Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.Multidrug resistance in European Clostridium difficile clinical isolates.Antimicrobial Susceptibility Patterns of Clostridium difficile Isolates from Family Dairy Farms.Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand.Rifaximin in the treatment of recurrent Clostridium difficile infection.Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong.Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.
P2860
Q26771995-A7602088-FDE2-4B22-A6F4-D11322AABC5CQ28082059-FF722ADC-7D37-4E69-A817-B7E3D319C943Q28084026-9C208A66-E782-4EEA-89B2-10ED4FC041FEQ28655729-29D79F28-9E7E-4790-BCB7-30D769D52217Q34409185-8012912C-A10B-4F63-B419-9719D5EC28DCQ34737357-2CC5F603-F395-4619-8FC1-B4814CA025C4Q35044119-4DB20FE2-4A06-4FB0-A317-4D72BC061E3EQ35155775-F81F70FD-6C5F-444A-AB7E-9218177E3FBAQ36533648-85437560-A9C2-42CF-9B73-2DAA567717BEQ36889259-A486CC38-87A1-4362-8112-198DC20E7CFCQ36997707-5BBC1459-1827-4641-84A8-A2FD5D0A0A33Q37287190-15177BB9-B680-4113-8DCD-9ABD4EB08A1EQ37305032-2BE0A7F1-1DA1-47E8-B441-411763E4815FQ37827877-B67970E9-7478-4496-AB1B-D0C7CBFB6D84Q37866629-F4A42B9D-8368-4C17-9423-364BAB39E985Q37964009-3477F380-B9BF-42E6-B976-F8C92C4F0891Q39665248-FDEB8FC2-6255-46AC-A827-D1D93D802B54Q39727030-01C9D998-234D-495F-B009-9E6EB7B40F5CQ40591120-A6D85177-E436-4D28-897C-7C7731A81452Q40721471-3774A29D-D2E3-4C03-ACEA-895602116FF7Q46549136-BD066063-88AE-4EDD-A5CD-C21E802B9222Q47103184-0ABF112B-84F9-4A68-AD8A-64E43232C824Q47691053-28B02347-A617-4FCA-A465-EC792F4519F5Q53692769-449815A3-F65F-4134-B878-164C86816288Q55405974-75A9B9B1-C217-4580-BFA5-5EC5EC2C1313
P2860
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@en
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@nl
type
label
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@en
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@nl
prefLabel
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@en
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@nl
P2093
P2860
P921
P356
P1476
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
@en
P2093
Dhara Shah
Kevin W Garey
Miguel Salazar
Richard Rodrigue
P2860
P304
P356
10.1345/APH.1K675
P407
P577
2008-04-22T00:00:00Z